3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer
DOI:
https://doi.org/10.26641/2307-0404.2023.2.283254Ключові слова:
non-muscle invasive bladder cancer, hyperthermic intravesical chemotherapyАнотація
Cur rently, the search for additional organ-sparing methods of intravesical therapy for non-muscular-invasive bladder cancer (NMIBC) is actively continuing, which could become an effective alternative to standard treatment using the Bacillus Calmette-Guérin (BCG) vaccine. The aim of this work was to analyze the safety profile and long-term results of treatment of patients with the high-risk non-muscular-invasive bladder cancer who received adjuvant intravesical chemotherapy using the Combat BRS HIVEC® device for local hyperthermia (HIVEC® therapy group; n=53) in comparison with patients who received adjuvant therapy after transurethral resection of bladder performed with the Bacillus Calmette-Guérin vaccine (BCG therapy group; n=54). As a result, the median follow-up was 30 months (range 7-36). According to Common Terminology Criteria for Adverse Events (CTCAE) v 5.0, the most relevant side effects in HIVEC®/BCG therapy groups were adverse events grade 1-2: fever – 1%/8%; dysuria – 9%/13%; bladder spasms – 7%/12%; hematuria – 3%/4% and urinary tract infection – 3%/10%. Tumor recurrence was reported in 23 patients receiving intravesical BCG therapy and in 10 patients receiving intravesical hyperthermic chemotherapy (42.6% versus 18.9%, p=0.008). Tumor progression was recorded in 11 patients receiving intravesical BCG therapy and in 4 patients receiving intravesical hyperthermic chemotherapy (20.4% versus 7.5%, p=0.046). The study allows us to conclude that the method of hyperthermic intravesical chemotherapy has a better safety profile compared to intravesical Bacillus Calmette–Guérin vaccine therapy, while such indicators of oncological efficacy as 3-year recurrence-free survival and the incidence of progression were better in the HIVEC® therapy group.
Посилання
Vozianov SA, Shamrayev SN, Stus VN, Krasnov VN, Vasylieva VD, Polion NYu, Shamrayeva DN. [Radical cystectomy: a comparative evaluation of perio-perative outcomes in patients with a complicated and uncomplicated postoperative period]. Zdorov'e muzhchiny. Russian. 2017;2:100-4. doi: https://doi.org/10.30841/2307-5090.2(61).2017.116643
Sharashova EE, Kholmatova KK, Gorbatova MA, Grjibovski AM. [The application of multiple logistic regression analysis in health sciences using SPSS software]. Nauka i zdravookhranenie. Russian. 2017;3:5-31. doi: https://doi.org/10.34689/SH.2020.19.4.001
Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) – 2019 Update. Eur Urol. 2019 Nov;76(5):639-57. doi: https://doi.org/10.1016/j.eururo.2019.08.016
Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genitourinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014 Jan;65(1):69-76. doi: https://doi.org/10.1016/j.eururo.2013.07.021
Kramer MW, Altieri V, Hurle R, Lusuardi L, Merseburger AS, Rassweiler J, et al. Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer. Eur Urol Focus. 2017 Dec;3(6):567-76. doi: https://doi.org/10.1016/j.euf.2016.12.004
Larsen ES, Nordholm AC, Lillebaek T, Hol-den IK, Johansen IS. The epidemiology of bacille Calmette-Guérin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int. 2019 Dec;124(6):910-6. doi: https://doi.org/10.1111/bju.14793
Parker WP, Smelser W, Lee EK, Habermann EB, Thapa P, Zaid HB, et al. Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients. Clin Genitourin Cancer. 2017 Aug 1:S1558-7673(17)30208-2. doi: https://doi.org/10.1016/j.clgc.2017.07.011
Plata A, Guerrero-Ramos F, Garcia C, González-Díaz A, Gonzalez-Valcárcel I, de la Morena JM, et al. Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain. J Clin Med. 2021 Oct 30;10(21):5105. doi: https://doi.org/10.3390/jcm10215105
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4;71(3):209-49. doi: https://doi.org/10.3322/caac.21660
Tan WS, Panchal A, Buckley L, Devall AJ, Lou-bière LS, Pope AM, et al. Radiofrequency-induced Thermochemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. Er Uruol. 2019 Jan;75(1):63-71. doi: https://doi.org/10.1016/j.eururo.2018.09.005
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2023 Медичні перспективи
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.